AIM: To evaluate the outcomes of >= 6y ranibizumab therapy in neovascular @entity1020 ( @entity1020 ). METHODS: HELIX was a retrospective, observational effectiveness study using medical records of @entity1 treated in three clinics in Belgium. @entity1 had @entity1020 and were initially treated with intravitreal ranibizumab (0.5 mg) between November 1, 2007 and October 31, 2008, had >= 6y of data available, and were treated on an ongoing, as-needed basis. Outcomes included best-corrected visual acuity (BCVA) and @entity989 ( @entity989 ). RESULTS: The sample consisted of 88 eyes from 69 @entity1 . Mean age was 76.4  6.5y, most @entity1 were female (62.3%). Most eyes (62.5%) were treatment-naive, 33 previously treated eyes had received predominantly other anti- @entity7 agents and @entity4936 . Mean baseline BCVA was 57.4  12.7 ETDRS letters and @entity989 was 291.5  86.1  m. On average, @entity1 received 20.6  11.9 ranibizumab injections over the >= 6y. Intervals between injections were on average 12.7  16.1wk. Mean change in BCVA from baseline to last observation for the sample was less than one letter (-0.9  17.3 letters), with an average loss of -3.2  15.6 letters in previously treated eyes versus a gain of 0.6  18.4 letters in treatment-na  ve eyes. When considering a loss of <15 letters over 6y as stabilization of disease, 75.9% of all eyes showed a positive (improvement or stabilization) outcome. Mean change in @entity989 from baseline to last observation for the sample was -26.9  148.4  m with the greatest reduction observed in treatment-naive eyes. CONCLUSION: This retrospective study of 69 @entity1020 @entity1 treated for >= 6y with ranibizumab demonstrates long-term visual stabilization. In light of the natural evolution of the disease, these data confirm that ranibizumab is effective long-term under real-world conditions of heterogeneity of @entity1 , clinicians, and centers.

Six-year outcomes in neovascular XXXX with ranibizumab.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4936 :: ('MESH:C098350', 'Chemical') :: ['verteporfin'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity989 :: ('MESH:D012164', 'Disease') :: ['CRT', 'central retinal thickness'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['neovascular AMD', 'AMD', 'age-related macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['age-related macular degeneration']
